▼ PAXLOVID® (nirmatrelvir; ritonavir) is authorised in Northern Ireland

PAXLOVID® is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

[Read the PAXLOVID® Package Leaflet: Information for the Patient](#) ❯

[PAXLOVID® Expiry Date Information](#) ❯

Ensuring the Authenticity of PAXLOVID®

Authentic PAXLOVID® from Pfizer will include the Pfizer name on the outer carton and will be packaged in 5 aluminium push-through blister cards. To ensure that the tablets are legitimate, look for specific text debossed on each side of the tablets. Nirmatrelvir tablets are pink, oval-shaped and debossed with 'PFE' on one side and '3CL' on the other side. Ritonavir tablets are white to off white, capsule shaped, and debossed with 'H' on one side and 'R9' on the other side.

The flaps at each end of the carton are glued as a tamper evident feature of the packaging.

The outer carton has a colourless, glossy coating that contains a repeated pattern of the Pfizer name and logo all over. The Pfizer name and logo appear in a contrasting matte finish.

If you suspect the PAXLOVID® you have received may be counterfeit, please report this to your local representative on +44 (0) 1304 616161.

ADVERSE EVENT REPORTING ▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. This includes any possible side effects not listed in the package leaflet. If you get any side effects talk to your doctor, pharmacist or nurse. You can also report any side effects directly via the Coronavirus Yellow Card Reporting site https://coronavirus-yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.